Innovation in medicines & leadership in exports
Pharmaceutical Boehringer Ingelheim was established in 1885 and is now among the world’s top 20 pharmaceutical companies. The company has recently been named one of the top 100
innovative companies of all industrial sectors. In Greece, the firm was founded in 1966 and is considered to be a market leader among the country’s top 10 pharmaceutical companies, while it has awarded several times both in Greece and abroad for its successful launches of innovative products including respiratory, cardiovascular, pain management, and recently Diabetes , Oncology and rare diseases.
Boehringer Ingelheim Ellas is also considered to be an innovation leader as it participates actively in the parent company’s international clinical research program. Among various awards, Boehringer Ingelheim Ellas received the Prix Galien award 2019, for its innovation in the field of rare diseases .
Boehringer Ingelheim Ellas SA is the only subsidiary of a multinational company in Greece that has been posting growing sales in recent years, amidst adverse conditions in the domestic market, helped primarily by its strong exports. Notably, the firm posted a high level of 2019 Total sales of 576,3 Euro , mainly as a result of high exports which reached 498,5 mio Euro, showing a notable 93,5% increase versus 201.
The company owns its production facility in Koropi, Attica, established in 1975 setting new standards in the country’s industrial sector. Today, it is the only multinational pharmaceutical company that maintains its industrial production facility in Greece, supplying not only the Greek market but also the markets of more than 70 countries. Its export activity is of particular importance not only to the firm itself, but also to the country’s economy, as it accounts for over 1, 12 % of total Greek exports, establishing Boehringer Ingelheim Ellas as a production & exports leader.
Its parent company recently entrusted Boehringer Ingelheim Ellas to transform its plant to a hub for the production of innovative antidiabetic drugs at the Greek plant, aimed at covering a large part of its international production, which is a ‘first’ in the company’s history. For this purpose, significant investments took place in order to expand the plant. Boehringer Ingelheim invested in total 80 mio Euro within crisis years in order to transform the plant to a hub. For this significant investment, Boehringer Ingelheim received in 2019 the Prix Galien distinction for the most significant investment in Pharmaceutical industry
Such actions and investments in production and export activity by Boehringer Ingelheim Ellas – with exports being its strong asset, stand proof of the confidence shown by the German multinational and its intention not only to upgrade its Greek subsidiary, but also to support and boost Greek exports. Boehringer Ingelheim Ellas’ initiatives for Greece’s economy are summarized in the triptych:
“We Invest, We Grow, We Support.” Boehringer Ingelheim has invested in Greece within the years of crisis almost 100 mio Euros, proving its sustainability profile. Last but not least, the firm’s human resources, more than 550 people, comprise leading scientists and sector professionals with the required skills, education and experience to implement its objectives and promote its vision, “Value through Innovation”.